key: cord-1002296-fpes9crq
authors: Masuda, Taisei; Murakami, Kyoko; Sugiura, Kenkichi; Sakui, Sho; Philip Schuring, Ron; Mori, Mitsuhiro
title: A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report
date: 2022-02-08
journal: Vaccine
DOI: 10.1016/j.vaccine.2022.02.030
sha: e53ece39278272bde42540361566de522452b656
doc_id: 1002296
cord_uid: fpes9crq

INTRODUCTION: The mRNA vaccine, mRNA-1273/TAK-919, encodes the prefusion-stabilised spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report interim results of the first study evaluating safety and immunogenicity of mRNA-1273 in healthy Japanese participants. METHODS: This phase 1/2, randomised, observer-blind, placebo-controlled trial, conducted in Japan (two sites), enrolled healthy adults aged ≥ 20 years with no prior exposure to investigational coronavirus vaccines/treatments, and no known history/risk of SARS-CoV-2 infection. Participants were stratified by age (< 65/≥ 65 years) and randomised to receive two doses of 100 μg mRNA-1273 or placebo administered as intramuscular injections 28 days apart. Primary outcomes were safety and immunogenicity assessed by anti-SARS-CoV-2-spike protein-binding antibody level (bAb). A secondary outcome was SARS-CoV-2 neutralising antibody (nAb) response. RESULTS: Participants were enrolled between 21 January and 3 February 2021, and 200 were randomised: mRNA-1273, n = 150 (< 65 years, n = 100; ≥ 65 years, n = 50); placebo, n = 50 (< 65 years, n = 40; ≥ 65 years, n = 10). Solicited adverse events (AEs) through 7 days after each vaccination occurred in 144/150 (96%) and 19/50 (38%) participants in the mRNA-1273 and placebo arms, respectively. In the mRNA-1273 arm, injection-site pain, myalgia and fatigue were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with mRNA-1273 (n = 147) with a bAb geometric mean fold rise (95% confidence interval [CI]) from baseline of 1009 (865, 1177) and a nAb of 21.7 (19.8, 23.8) at day 57. Seroconversion rates (95% CI) for bAb and nAb were both 100% (97.5, 100) at day 57. No such response occurred with placebo (n = 49). CONCLUSION: Two doses of 100 μg mRNA-1273 given 28 days apart demonstrated an acceptable safety profile and induced significant anti-SARS-CoV-2 immune responses in a Japanese population aged ≥ 20 years. Funding: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). ClinicalTrials.gov: NCT04677660.

As of August 2021, there have been over 205 million confirmed cases of the novel coronavirus disease 2019 (COVID-19) and over 4.3 million deaths attributed to the disease worldwide [1] . In Japan, there have been over 1 million confirmed cases of COVID-19 with over 15,000 deaths reported [2] . To date, more than 6.5 billion vaccine doses have been administered worldwide [1] .

mRNA-1273 is a lipid-nanoparticle encapsulated mRNA vaccine encoding a pre-fusion stabilised form of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S-2P). To date, preclinical and clinical evaluations have demonstrated that mRNA-1273 is well tolerated, is immunogenic, and drives a robust SARS-CoV-2-specific antibody and T-cell response [3] [4] [5] [6] [7] [8] . In a recent phase 3 study of 30,420 volunteers in the USA, two doses of 100 μg mRNA-1273 were shown to be 94.1% effective (95% confidence interval [CI]: 89.3, 96.8;

P<0.001 vs placebo) at preventing COVID-19 illness, including severe disease [5] .

At the time of writing, mRNA-1273 is currently being used as part of the COVID-19 vaccination programme in several countries. In December 2020, the USA Food and Drug Administration issued emergency-use authorisation for mRNA-1273 for the prevention of COVID-19 for individuals ≥18 years of age, with the UK also granting approval in January 2021 [9, 10] . In Japan, mRNA-1273 received special approval in May 2021 [11] .

As part of the vaccine registration process in Japan, we conducted a phase 1/2 study of mRNA-1273 (development code in Japan: TAK-919) in healthy Japanese adults (aged ≥20 years) to evaluate the safety and immunogenicity of two doses of 100 μg mRNA-1273, given 28 days apart. The participants are to be followed up for 12 months after the second dose. Herein, we report results from the primary analysis of the data at the 4-week follow-up after the second dose (up to day 57), ahead of completion of the 12-month follow-up period. This is the first TAK919/mRNA-1273 manuscript Vaccine 5 report of the safety and immunogenicity of mRNA-1273 in healthy Japanese adults aged ≥20 years.

This was a phase 1/2 randomised, observer-blind, placebo-controlled trial, conducted at two centres in Japan to evaluate the safety and immunogenicity of two doses of mRNA-1273 (TAK-919) in Japanese adults (ClinicalTrials.gov, NCT04677660). The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the

Practice and all applicable regulations. An institutional review board, which covered both participating sites, approved the study protocol. All participants provided written informed consent.

Eligible participants were Japanese adults aged ≥20 years who were in good health as determined by medical history, physical examination (including vital signs and laboratory tests) and clinical judgement of the investigator. Participants were excluded if they received any other SARS-CoV-2 vaccines or other experimental novel coronavirus vaccine, had been in close contact with anyone known to have COVID-19 within 30 days before study vaccination, or were positive for SARS-CoV-2 infection before the trial. The trial design was developed in accordance with the guidance from the Pharmaceuticals and Medical Devices Agency [12] .

Randomisation was undertaken according to randomisation tables generated by sponsor randomisation personnel or an unblinded designee. Participants were randomised (3:1) to the TAK919/mRNA-1273 manuscript Vaccine mRNA-1273 arm or placebo arm and were stratified by age: ≥20 years to <65 years (mRNA-1273, n=100; placebo, n=40); ≥65 years (mRNA-1273, n=50; placebo, n=10).

As an observer-blinded trial, the participants, data collectors (e.g., investigators) and data evaluators were blinded to the trial-group assignment. Designated site personnel had access to the trial-group assignments to manage and prepare the trial vaccines but were not involved in data collection or safety evaluation after vaccine administration. Once day 57 data from all participants were collected, the database was locked, and the trial was unblinded (switched to an open-label study). Participants were informed about the vaccination assignment (mRNA-1273 or placebo) and reconsent was obtained for them to continue the study. Any participants who received an approved SARS-CoV-2 vaccine while enrolled on the trial (either during the double-blind phase up to the database lock of day 57 or the open-label phase after the database lock) were terminated from the trial.

Participants received deltoid intramuscular injection (injection volume, 0.5 mL; needle diameter, 25G; needle length, 1 inch [2.54 cm]) of either two doses of 100 µg mRNA-1273 vaccine or two doses of saline placebo on day 1 and day 29 (28±3 days after the first vaccination; Figure 1 ).

Additional information regarding the mRNA-1273 vaccine is provided in the Supplementary Information. All participants were to be followed up with in-person visits on day 1 (day of first 

For 7 days after each injection (including the day of injection), participants self-reported oral body temperature and solicited local and systemic adverse events (AEs) in an eDiary. Solicited TAK919/mRNA-1273 manuscript Vaccine local AEs were defined as injection-site pain, erythema/redness, swelling, induration, and axillary swelling or tenderness ipsilateral to the side of injection. Solicited systemic AEs were headache, fatigue, myalgia, arthralgia, nausea/vomiting, chills, and fever. Data regarding unsolicited AEs were collected for 28 days after each injection (day of injection and 27 subsequent days). Solicited AEs occurring between 7-27 days after injection was classified as unsolicited AEs. In addition, all participants were to be followed for serious AEs (SAEs), medically attended AEs (MAAEs), and AEs leading to trial withdrawal or discontinuation from informed consent throughout the study (day 1 to day 394). The Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials [13] was used in this study with minor modifications for solicited AEs. Blood samples for safety laboratory tests were taken on days 1, 8, 29, 43 and 57 with standard haematology and blood chemistry tests performed. At prespecified time points (days 1, 29, and 57) and where clinical symptoms of COVID-19 were suspected, participants were tested for SARS-CoV-2 infection by polymerase chain reaction test.

Immunogenicity was to be assessed in blood samples collected on day 1 (before injection) and on days 29 (before injection), 43, 57, 209 and 394. The assay methods used have been previously published [6] . Briefly, SARS-CoV-2-binding antibody (bAb) levels were measured by an enzyme-linked immunosorbent assay (ELISA) specific to S-2P (collaborative development with PPD laboratories, Richmond, VA, USA). Interpolation from an 11-point dilution of a commercial anti-S-2P monoclonal antibody (clone CR3022, Rockland, Inc, Limerick, PA, USA) was used to determine the serum-derived anti-S-2P antibody concentration (AU/mL). Serum neutralising antibody (nAb) titres against SARS-CoV-2 were measured using a live virus microneutralisation (MN) assay based on an in situ ELISA readout. The assay was conducted in accordance with Battelle laboratory protocols and qualified critical reagents (Columbus, Ohio, TAK919/mRNA-1273 manuscript Vaccine 8 USA). The 50% MN titre (MN 50 ) was reported for each sample. While the assays were qualified in the previous study [9] , both bAb and nAb assays were fully validated at initiation for this study.

In the present study, the primary safety outcome measures were: solicited AEs through 7 days after each vaccination; unsolicited AEs through 28 days after each vaccination; MAAEs, SAEs, AEs leading to discontinuation of vaccination and AEs leading to participant withdrawal from the trial through day 57; and proportion of participants with SARS-CoV-2 infection through day 57.

The primary immunogenicity outcome measure was serum bAb levels against SARS-CoV-2 on day 57. The key secondary immunogenicity outcome measures were serum bAb levels and serum nAb titres against SARS-CoV-2 throughout the follow-up period (except for serum bAb level on day 57, which was the primary outcome measure). Only data to day 57 are available to date.

The trial planned to enrol 200 participants, 150 in the mRNA-1273 arm and 50 in the placebo arm. No formal statistical power calculations were performed to determine the sample size. The sample size for the trial was considered sufficient with a 95% probability of observing at least one AE with a 2% event rate in the mRNA-1273 arm. The interim analysis was performed for safety and immunogenicity after all participants had completed the day 57 visit (data cut-off date: 31 March 2021). The full analysis set (FAS) and safety analysis set (SAS) each included all randomised participants who received at least one treatment dose, and the per protocol set (PPS) included participants in the FAS who received two treatment doses, had evaluable TAK919/mRNA-1273 manuscript Vaccine immunogenicity data and had no significant protocol deviations. All safety summaries were presented by treatment group based on the SAS, and unsolicited AEs were coded using the Medical Dictionary for Regulatory Activities dictionary version 24.0. For the immunogenicity endpoints, geometric mean titre (GMT), geometric mean fold rises (GMFR), and seroconversion rate (SCR; defined as percentage of participants with a change from below the lower limit of quantification [LLOQ, 1.0 AU/mL for bAb and 159.79 for nAb] to equal to or above LLOQ, or a ≥ 4-fold rise from baseline), and their respective 95% CIs were analysed in the PPS. Antibody values reported as below LLOQ were replaced by 0.5 × LLOQ. Values that were greater than the upper limit of quantification (ULOQ; 2052 AU/mL for bAb and 11173.11 for nAb) were replaced by the ULOQ. Sub-analyses by age groups (≥20 years to <65 years or ≥65 years) and sex (male or female) were performed for solicited AEs, unsolicited AEs and immunogenicity analyses. All analyses were conducted using SAS version 9.4.

A total of 319 participants were screened between 21 January 2021 and 3 February 2021 and 200 participants were randomised (150 participants in the mRNA-1273 arm and 50 participants in the placebo arm; Figure 2 ). In the mRNA-1273 arm, 147/150 (98.0%) participants received both doses of vaccine. Three participants (2.0%) did not receive a second vaccination in the mRNA-1273 arm due to adverse events (injection-site rash in two participants; injection-site pain, fatigue, arthralgia, headache and axillary pain in 1 participant). Despite not receiving their second vaccinations, the three participants in the mRNA-1273 arm agreed to continue with safety assessments during the follow-up period. All participants received both vaccinations in the placebo arm and no participants discontinued from the study by 31 March 2021, the data cut-off date for this interim analysis. All 200 participants were included in the SAS and FAS; and TAK919/mRNA-1273 manuscript Vaccine 50 (98.0%) participants from the placebo arm. In total, 4 participants were excluded from the PPS: 3 in the mRNA-1273 arm because they did not receive a second vaccination and 1 in the placebo arm because their day 57 visit could not be completed by the data cut-off date.

The baseline characteristics were generally balanced across the mRNA-1273 and placebo arms and in each age group ( Solicited local and systemic AEs through day 7 were mainly mild (grade 1) or moderate (grade 2) in severity in both arms after the first and second injections ( Figure 3A; Table 2 ). In the mRNA-1273 arm, the incidence of grade 2 or 3 solicited AEs increased after the second injection, particularly for systemic AEs. After the second vaccination, the incidence of grade 3 or In the mRNA-1273 arm, injection-site pain was the most frequently reported solicited local AE after both the first and second vaccination and in both age groups (≥20 years to <65 years, after the second vaccination in the mRNA-1273 arm in both age groups (Figure 3) .

Unsolicited AEs were reported in 45/150 (30.0%) participants who received mRNA-1273 and 11/50 (22.0%) participants who received placebo ( Table 3) MAAEs were reported in 7/150 (4.7%) participants who received mRNA-1273 and in 1/50 (2.0%) of participants who received placebo. The only MAAE reported by ≥2 participants in the mRNA-1273 arm was dental caries. No noteworthy differences by age group (≥20 to <65 years or ≥65 years) were observed in the unsolicited AE profile across the arms. No deaths, SAEs or AEs leading to a participant's withdrawal from study occurred in the 28 days after any injections.

AEs leading to discontinuation from vaccination were reported in 3 participants in the mRNA-1273 arm. No SARS-CoV-2-infected participants were reported through to the data cut-off date.

There were no clinically meaningful changes in safety clinical laboratory tests in either groups.

In the mRNA-1273 arm, alanine aminotransferase increased, and aspartate aminotransferase increased were reported in 1 participant each (0.7%) as unsolicited AEs. These events were grade 1 in severity, resolved, and were considered to be unrelated to treatment (data not shown).

Two doses of 100 μg mRNA-1273 given 28 days apart resulted in the induction of bAb for S-2P in all 147 (100%) participants from baseline by day 57, in the primary immunogenicity analysis.

No such induction of bAb was observed in the placebo group ( For SCR, defined as percentage of participants with a change from below the LLOQ to equal to or above LLOQ, or a ≥ 4-fold rise from baseline the placebo arm showed a 2.0% (95% CI: 0.1, 10.9) SCR on day 57 (Table 4) 

This was the first phase 1/2 study to assess the safety and immunogenicity of mRNA-1273 in healthy Japanese adults aged 20 years or older. Two doses of 100 μg mRNA-1273 administered 28 days apart exhibited robust immune responses and an acceptable safety profile that was in line with US phase 2 and 3 mRNA-1273 studies [5, 6] . Based on the data from the present study and the US data, mRNA-1273 was approved for emergency use in Japan in May 2021 [11] .

Local and systemic adverse events were predominantly grade 1-2 in severity, generally resolved within three days, and occurred at a similar incidence irrespective of age. While we must be careful in our assessment due to the difference in sample size between the studies, the incidence rate of some solicited AEs including grade 3 and grade 4 fever tended to be higher in this phase 1/2 study in a Japanese population compared with the phase 3 study in the USA.

The incidence rates of any grade, grade 3 and grade 4 fever post second vaccination were 40.1% (59/147 participants), 4.8% (7/147 participants), and 0.7% (1/147 participants) in the present study versus 17.4% (1806/10352 participants), 1.6% (168/10352 participants), and <0.1% (10/10352 participants) in the US phase 3 study [5, 14] . However, the majority of solicited AEs in the mRNA-1273 group were grade 1-2 in severity and generally resolved within a few days in both studies. The difference in incidence rate of solicited AEs might be due to the same vaccine dose being administered to participants in Japan and US irrespective of mean body mass, which was higher among the US participants [15] . In the present study, mean body mass index was 22.39 (±2.65) kg/m 2 in the mRNA-1273 arm whereas in the US study participants had a mean body mass index of 29.3 (±6.9) kg/m 2 [5] . No specific concerns for the Japanese population were raised with regard to the unsolicited AEs identified. Hence, there was no clinically significant difference in safety profile between the Japanese phase 1/2 and US phase 3 study.

Delayed-onset local reactions (defined as those with an onset on or after day 8) after either the first or second dose of mRNA-1273 were reported in both the US phase 3 study (rate after first dose, 0.8% [244/30,420 participants]; rate after second dose 0.2% [68/30,420 participants]) and in a subsequent case series [5, 16] . In the present study, we observed 8 relevant cases as described in the results, all of which were grade 1-2 in severity and resolved within the follow-up periods. The exact mechanism underlying delayed-onset local reactions is not known; however, delayed-type or T-cell mediated hypersensitivity is hypothesised [16] . Although such delayed reactions may be worrisome for people receiving the vaccine, neither delayed hypersensitivity reaction nor local injection-site reactions are considered contraindications to future doses [17] , and administration of the second vaccine dose is considered prudent given the robust acquired immune response we observed post-second dose.

In the present study, Japanese adults who received two doses of 100 μg of mRNA-1273 given 28 days apart induced robust immune response for both binding and neutralising antibodies against the recombinant S-2P protein or wild-type virus by day 57, with GMFRs >1000-fold (bAb) and >20-fold (nAb) respectively. In the present study, anti-S-2P bAb and nAb were produced in response to both doses of mRNA-1273 within 28 days (day 29) after the first vaccination, rising to peak titres by 14 days after the second vaccination (day 43) and then remaining elevated to day 57. SCR was 100% at day 57. A similar response pattern and time course was reported in a phase 2 study of mRNA-1273 conducted in healthy adults in the USA [6] .

While vaccine efficacy (prevention of symptomatic virus infection) was not investigated in the present study, the immunogenicity findings and response patterns observed were similar to those observed in the phase 2 [6] and phase 3 (unpublished data) US studies, so we would anticipate that mRNA-1273 would achieve similar vaccine efficacy in Japanese populations. In a phase 3 US study of 30,420 volunteers of whom 2.2% had evidence of SARS-CoV-2 infection (serologic or virologic, or both) at baseline, mRNA-1273 (100 μg) vaccine efficacy was shown to be 94.1% (95% CI: 89.3, 96.8; P<0.001) [5] . These findings further support the use of mRNA-1273 in the Japanese population.

Nevertheless, given the continued evolution of the SARS-CoV-2 virus, it is vital that further research is conducted to assess the efficacy of 100 μg mRNA-1273 against variants [18, 19] , and to examine safety and efficacy in paediatric populations. We acknowledge several limitations of our study. Because of the precautionary nature of phase 1/2 studies, our study was restricted by its small sample size and the efficacy of the vaccine as prophylaxis for COVID-19 was not assessed. Moreover, the study included only healthy adult participants aged ≥20 years so caution should be used when extrapolating results to populations with comorbid diseases that impact immune response, or in paediatric populations. Percentages are based on the number of randomised participants. Table 2 . Solicited adverse events within 7 days after injections (safety analysis set). Tables   Table 3 . Summary of unsolicited adverse events by treatment arm and injections (safety analysis set). 

World Health Organization. COVID-19 statistics 2021: Global

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

US Food and Drug Ad. Moderna COVID-19 Vaccine

Covid-19: UK approves Moderna vaccine to be given as two doses 28 days apart

Pharmaceuticals and Medical Devices Agency (PMDA)

Principles for the evaluation of vaccines against the novel coronavirus SARS-CoV-2

Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials

US Food and Drug Administration Briefing Document. Vaccines and Related Biological Products Advisory Committee Meeting December 17, 2020: Moderna COVID-19 Vaccine

Association between COVID-19 Vaccine Side Effects and Body Mass Index in Spain. Vaccines (Basel)

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2

Adverse reactions to vaccines practice parameter 2012 update

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

GMFR (95% CI) 175 (149, 205) 196

GMT (95% CI) 1022 (941, 1110) 1024 (931, 1126) 1017

GMFR (95% CI) 1268 (1073, 1498) 1311 (1080, 1592) 1187

GMT (95% CI) 813

GMFR (95% CI) 1009 (865, 1177) 1038

The authors would like to thank the study participants, the investigators, Dr Ryuzo Hanada (Souseikai Sumida Hospital, Tokyo, Japan) and Dr Miwa Haranaka (Souseikai PS Clinic, Fukuoka, Japan) and staff at the study sites for their valued contribution to this study. Medical 

All authors are employees of Takeda Pharmaceutical Company Ltd with the exception of RS, who is an employee of Takeda Pharmaceutical International Ag.

AU = arbitrary unit, bAb = binding antibody, CI = confidence interval; GMFR = geometric mean fold rise, GMT = geometric mean titre, IgG = immunoglobulin G, LLOQ = lower limit of quantification, MN50 = 50% microneutralisation titre, nAb = neutralising antibody, SARS-CoV-2 = severe acute respiratory syndrome coronavirus-2, SCR = seroconversion rate, ULOQ = upper limit of quantification. a Serum bAb Against SARS-CoV-2 as measured by ligand-binding assay specific to the SARS-CoV-2 S-protein (VAC65 Spike IgG Antibody